Review Article
The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease
Table 2
Studies on the regulatory mechanism of CHM in the treatment of DKD.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviations: CHM: Chinese herbal medicine; DKD: diabetic kidney disease; DHI: Danhong injection; IRS1: insulin receptor substrate 1; FGF21: fibroblast growth factor 21; PPARγ: peroxisome proliferator-activated receptor γ; SREBP-1c: sterol regulatory element-binding protein-1c; ACC: acetyl-CoA carboxylase; FAS: fatty acid synthase; SYFSF: Shen-Yan-Fang-Shuai Formula; TNF-α: tumor necrosis factor-alpha; NF-κB: nuclear factor-kappa B; ECM: accumulation of extracellular matrix; MC: Moutan Cortex; RAGE: receptor of advanced glycation end products; IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; TGF-β1: transforming growth factor beta1; ICAM-1: intercellular adhesion molecule-1; CAT: catalase; GSH-Px: glutathione peroxidase; TWH: Tripterygium wilfordii Hook. f; OCP: oxidative carbonyl protein; MDA: malondialdehyde; SOD: superoxide dismutase; NOX4: NAPDH oxidase 4; Hyp: hydroxyproline; PAI-1: plasminogen activator inhibitor type 1; CTGF: connective tissue growth factor; PERK: phosphorylated protein kinase RNA-like endoplasmic reticulum kinase; eIF2α: eukaryotic initiation factor 2α; AMPK: AMP-activated protein kinase; mTOR: mammalian target of rapamycin complex 1; ULK1: Unc-51-like kinase; Col IV: collagen IV; FN: fibronectin; E-CA: E-cadherin; α-SMA: α-smooth muscle actin; TLR4: Toll-like receptor 4; TRAF: tumor-necrosis factor receptor-associated factor. |